Document:

FOR
ACCREDITED INVESTORS ONLY

     

    FORM
OF SUBSCRIPTION DOCUMENTS AND INSTRUCTIONS

    

    INSTRUCTIONS

    

    The
following documents must be completed in accordance with the instructions set
forth below and must be executed in order to determine whether you are an
“accredited investor” as such term is defined in the Securities Act of 1933, as
amended, and, if so accredited, in order to subscribe for the purchase of
certain securities (the “Securities”) of
Cytomedix, Inc., a Delaware corporation (the “Company”), consisting
of: (i) shares of its 10% Series D Convertible Preferred Stock and (ii) a
warrant to purchase shares of Common Stock (a “Warrant”). Each
Warrant shall be exercisable for the number of shares of Common Stock set forth
in the Warrant at a price of $___ per share (or 110% of the 10 day volume
weighted average price preceding the closing of this Offering) for 5 years after
the Closing.

     

    1.           Instructions.

    

    (a)       
Subscription Agreement and
Registration Rights Agreement.   Be sure to carefully and
fully read the Subscription Agreement and the Registration Rights Agreement, and
execute the signature pages which are applicable to you. On the appropriate
signature pages, you must sign, print your name (or the name of the entity on
whose behalf you are signing), address and social security or tax identification
number where indicated, and indicate the number of Securities subscribed for,
the date of execution and the manner in which title to the Securities will be
held.

    

    (b)       
Confidential Investor
Questionnaire. Be sure to carefully and fully read the Confidential
Investor Questionnaire attached as Exhibit A to
Subscription Agreement. On the signature page of the Confidential Investor
Questionnaire, you must sign and print your name (or the name of the entity on
whose behalf you are signing) where indicated.

    

    2.           Return of
Documents.  Originals of the signed Subscription Agreement and
Confidential Investor Questionnaire should be delivered to the following
address:

    

    Cytomedix,
Inc.

    416
Hungerford Drive, Suite 330

    Rockville,
MD 20850

    Attention:  Andrew
Maslan, CFO

    Fax:
(240) 499-2690

    

    3.           Payment.  Contemporaneously
with the execution and delivery of the Subscription Agreement and the
Confidential Investor Questionnaire, payment of the purchase price may be made
by wire transfer of immediately available funds, to Cytomedix, Inc., as
follows:

    

    (see
separate wire transfer attachment)

    

    If you
should have any questions, please contact Andrew Maslan, CFO of the Company, at
the Company’s  principal executive offices located at 416 Hungerford
Drive, Suite 330, Rockville, MD 20850, or by telephone at (240)
499-2680.

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    PLEASE
PRINT:

    

    NAME OF SUBSCRIBER:                      ____________________________________

     

    AGGREGATE PURCHASE PRICE:      $________________

    

    SUBSCRIPTION
AGREEMENT

    

    This
Subscription Agreement, including Addendum A thereto (this
“Agreement”) is
being delivered to you in connection with your investment in Cytomedix, Inc., a
Delaware corporation, whose shares of common stock (the “Common Stock”) are
currently traded on the NYSE Amex LLC under the symbol “GTF.BC” (“the
Company”).  The Company is conducting a private placement (the
“Offering”) of
its securities (the “Securities”),
consisting of (i) shares of the 10% Series D Convertible Preferred Stock (the
“Preferred
Stock”) and (ii) a warrant to purchase shares of Common Stock (a “Warrant”).  Each
Warrant shall be exercisable for the number of shares of Common Stock set forth
in the Warrant at a price per share equal to 110% of the 10 day volume weighted
average price preceding the closing of the Offering and for 5 years after the
Closing.

    

    All funds
received in the Offering prior to the Closing (as defined below) shall be, upon
fulfillment of the other conditions precedent set forth herein, delivered to the
Company, at which time the Preferred Stock and the Warrants subscribed for shall
be delivered, subject to the terms and provisions hereof and as further
described below, to you.

    

    1.            
Subscription and Purchase
Price

    

    (a)           Subscription. Subject
to the conditions set forth in Section 2 hereof, the
undersigned hereby subscribes for and agrees to purchase that number of shares
of the Preferred Stock as set forth on the Signature Page to this Agreement on
the terms and conditions described herein. The principal dollar amount of the
undersigned’s investment hereunder is $________; the undersigned shall also be
entitled to receive a number of Warrants calculated as fifty percent (50)% of
the number of shares of Common Stock into which the Preferred Stock is
convertible at the Conversion Price (as the term is defined under the
Certificate of Designation of Relative Rights, Preferences and Other
Distinguishing Characteristics of the 10% Series D Convertible Preferred
Stock).

    

    (b)           Purchase of
Securities. The undersigned understands and acknowledges that the
purchase price to be remitted to the Company in exchange for the Securities
shall be $___________, for an aggregate purchase price as set forth on Page 9
hereof (the “Aggregate
Purchase Price”). The undersigned’s delivery of this Agreement to the
Company shall be accompanied by payment, to the Company, of the Aggregate
Purchase Price, payable in United States dollars, by wire transfer of
immediately available funds.  The undersigned understands and agrees
that, subject to Section 2 hereof and
applicable laws, by executing this Agreement, he, she or it is entering into a
binding agreement.

    

    2.            
Acceptance, Offering
Term and Closing Procedures

    

    (a)           Acceptance or
Rejection. The obligation of the undersigned to purchase the Securities
shall, subject to the investor accreditation process, applicable securities laws
and the closing conditions contained in Section 6 hereof, be
irrevocable and the undersigned shall be legally bound to purchase the
Securities subject to the terms set forth in this Agreement.  The
undersigned understands and agrees that the Company reserves the right to reject
this subscription for Securities in whole or in part in any order at any time
prior to the Closing if, in its reasonable judgment, it deems such action to be
in the best interest of the Company, notwithstanding the undersigned’s prior
receipt of notice of acceptance of the undersigned’s subscription. In the event
of rejection of this subscription by the Company in accordance with this Section 2, or the
sale of the Securities is not consummated by the Company for any reason, this
Agreement and any other agreement entered into between the undersigned and the
Company relating to the undersigned’s subscription for Securities shall
thereafter have no force or effect, and the Company shall promptly return or
cause to be returned to the undersigned the Aggregate Purchase Price remitted to
the Company, without interest thereon or deduction therefrom.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    (b)           Closing/Offering
Term. The subscription period for the Offering will begin as of April _,
2010. The closing of the Offering (the “Closing”) will occur
upon the earlier to occur of: (i) receipt of acceptable subscriptions equal to
at least Two Million ($2,000,000) or (ii) April __, 2010. The Offering will
terminate on April _, 2010, unless extended without notice by the
Company for no more than two 30 day periods thereafter.

    

    (c)           The
Company has retained and appointed Maxim Group LLC (“Maxim”) to act as its
exclusive placement agent (with right to retain subagents), on a “best efforts”
basis with respect to this Offering. Under the terms of our engagement letter
with Maxim, in connection with this Offering Maxim may be entitled to (i) a
commission of 8% of the gross proceeds received by the Company payable in cash
on the closing date(s); (ii) a warrant to purchase the number of shares of the
Company common stock equal to 4% of the number of shares of Common Stock
underlying the securities issued in this Offering, and (iii) certain
reimbursement of various offering related expenses in the amount not to exceed
$50,000.

    

    3.            
Investor’s
Representations and Warranties

    

    The
undersigned hereby acknowledges, agrees with and represents and warrants to the
Company, as follows:

    

    (a)           The
undersigned has full power and authority to enter into and deliver this
Agreement and to perform the obligations hereunder, and the execution, delivery
and performance of this Agreement has been duly authorized, if applicable, and
this Agreement constitutes a valid and legally binding obligation of the
undersigned.

    

    (b)           The
undersigned acknowledges his, her or its understanding that the offering and
sale of the Preferred Stock, the Warrants and the shares of common stock
underlying such Securities (the “Underlying
Securities”) is intended to be exempt from registration under the
Securities Act of 1933, as amended (the “Securities Act”), by
virtue of Section 4(2) of the Securities Act and the provisions of Regulation D
promulgated thereunder (“Regulation D”). In
furtherance thereof, the undersigned represents and warrants to the Company as
follows:

    

    (i)           The
undersigned realizes that the basis for the exemption from registration may not
be available if, notwithstanding the undersigned’s representations contained
herein, the undersigned is merely acquiring the Securities for a fixed or
determinable period in the future, or for a market rise, or for sale if the
market does not rise. The undersigned does not have any such
intention.

    

    (ii)          The
undersigned is acquiring the Securities solely for the undersigned’s own
beneficial account, for investment purposes, and not with view to, or resale in
connection with, any distribution of the Securities.

    

    (iii)     
   The undersigned has the financial ability to bear the economic
risk of his, her or its investment, has adequate means for providing for its
current needs and contingencies, and has no need for liquidity with respect to
the investment in the Company.

    

    (iv)      
  The undersigned and the undersigned’s attorney, accountant,
purchaser representative and/or tax advisor, if any (collectively, “Advisors”), have
received, carefully reviewed and understand the information contained in various
documents and agreements provided by the Company, together with all appendices
and exhibits thereto (as such documents may be amended or supplemented, the
“Transaction Documents”), relating to the Offering.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    (v)         The
undersigned (together with his, her or its Advisors, if any) has such knowledge
and experience in financial and business matters as to be capable of evaluating
the merits and risks of the prospective investment in the Securities. If other
than an individual, the undersigned also represents it has not been organized
solely for the purpose of acquiring the Securities.

     

    (c)           The
information in the Confidential Investor Questionnaire attached hereto as Exhibit A and
completed and executed by the undersigned is true and accurate in all respects,
and the undersigned is an “accredited investor,” as that term is defined in Rule
501(a) of Regulation D.

    

    (d)           The
undersigned is not relying on the Company or its affiliates or agents with
respect to economic considerations involved in this investment. The undersigned
has relied on the advice of, or has consulted with, only his, her or its
Advisors. Each Advisor, if any, is capable of evaluating the merits and risks of
an investment in the Securities, and each Advisor, if any, has disclosed to the
undersigned in writing (a copy of which is annexed to this Agreement) the
specific details of any and all past, present or future relationships, actual or
contemplated, between the Advisor or any affiliate or sub-agent
thereof.

    

    (e)           The
undersigned represents, warrants and agrees that he, she or it will not sell or
otherwise transfer the Securities without registration under the Securities Act
or an exemption therefrom, and fully understands and agrees that the undersigned
must bear the economic risk of his, her or its purchase because, among other
reasons, the Securities have not been registered under the Securities Act or
under the securities laws of any state and, therefore, cannot be resold,
pledged, assigned or otherwise disposed of unless they are subsequently
registered under the Securities Act and under the applicable securities laws of
such states, or an exemption from such registration is available. In particular,
the undersigned is aware that the Securities (including the Underlying
Securities) are “restricted securities,” as such term is defined in Rule 144
promulgated under the Securities Act (“Rule 144”), and they
may not be sold pursuant to Rule 144 unless all of the conditions of Rule 144
are met. The undersigned also understands that, except as otherwise provided in
Section 4
hereof, the Company is under no obligation to register the Securities on his,
her or its behalf or to assist them in complying with any exemption from
registration under the Securities Act or applicable state securities laws. The
undersigned understands that any sales or transfers of the Securities are
further restricted by state securities laws and the provisions of this
Agreement.

    

    (f)           The
undersigned understands and agrees that the certificates for the Securities
shall bear substantially the following legend until (i) the Securities
(including the Underlying Securities) shall have been registered under the
Securities Act and effectively disposed of in accordance with a registration
statement that has been declared effective or (ii) in the opinion of counsel for
the Company, the Securities (including the Underlying Securities) may be sold
without registration under the Securities Act, as well as any applicable “blue
sky” or state securities laws:

    

    THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE
STATE SECURITIES LAWS. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT
PURPOSES AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE,
TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FILED BY THE ISSUER WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION
COVERING SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL
SATISFACTORY TO THE ISSUER THAT SUCH REGISTRATION IS NOT
REQUIRED.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    (g)           No
representations or warranties have been made to the undersigned by the Company
or any of its respective officers, employees, counsel, agents, sub-agents,
affiliates or subsidiaries, other than any representations of the Company
contained in the transaction agreements in connection with the Offering, and in
subscribing for the Securities the undersigned is not relying upon any
representations other than those contained in the transaction agreements in
connection with the Offering.

    

    (h)           The
undersigned understands and acknowledges that his, her or its purchase of the
Securities is a speculative investment that involves a high degree of risk and
the potential loss of the undersigned’s entire investment and has carefully read
and considered the matters set forth in the agreements in connection with the
Offering, and, in particular, acknowledges that the Company has a limited
operating history.

    

    (i)  
         The undersigned’s overall
commitment to investments that are not readily marketable is not
disproportionate to the undersigned’s net worth, and an investment in the
Securities will not cause such overall commitment to become
excessive.

     

    (j)    
       Neither the U.S. Securities and
Exchange Commission (the “SEC”) nor any state
securities commission has approved the Underlying Securities or passed upon or
endorsed the merits of the Offering or confirmed the accuracy or determined the
adequacy of the agreements in connection with the Offering. The agreements in
connection with the Offering have not been reviewed by any federal, state or
other regulatory authority. Any representation to the contrary is a
crime.

    

    (k)           The
undersigned and his, her or its Advisors, if any, have had a reasonable
opportunity to ask questions of and receive answers from a person or persons
acting on behalf of the Company concerning the offering of the Securities and
the business, financial condition, results of operations and prospects of the
Company, and all such questions have been answered to the full satisfaction of
the undersigned and his, her or its Advisors, if any.

    

    (l)         
  The undersigned is unaware of, is in no way relying on, and did not
become aware of the offering of the Securities through or as a result of, any
form of general solicitation or general advertising including, without
limitation, any article, notice, advertisement or other communication published
in any newspaper, magazine or similar media or broadcast over television or
radio, or electronic mail over the Internet, in connection with the offering and
sale of the Securities and is not subscribing for Securities and did not become
aware of the offering of the Securities through or as a result of any seminar or
meeting to which the undersigned was invited by, or any solicitation of a
subscription by, a person not previously known to the undersigned in connection
with investments in securities generally.

    

    (m)          The
undersigned has taken no action which would give rise to any claim by any person
for brokerage commissions, finders, fees or the like relating to this Agreement
or the transactions contemplated hereby (other than commissions to be
potentially paid by the Company to Maxim Group, LLC, its sub-agents or as
otherwise described in the agreements in connection with the
Offering).

    

    (n)  
        The undersigned is not relying on the
Company or any of its respective employees, agents or sub-agents with respect to
the legal, tax, economic and related considerations of an investment in the
Securities, and the undersigned has relied on the advice of, or has consulted
with, only his, her or its own Advisors.

    

    (o)     
     The undersigned acknowledges that any estimates or
forward-looking statements or projections included in the Transaction Documents
were prepared by the management of the Company in good faith, but that the
attainment of any such projections, estimates or forward-looking statements
cannot be guaranteed by the Company or its respective management and should not
be relied upon.

    

    (p)        
  No oral or written representations have been made, or oral or written
information furnished, to the undersigned or his, her or its Advisors, if any,
in connection with the offering of the Securities which are in any way
inconsistent with the information contained in the agreements in connection with
the Offering.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

    (q)        
  The undersigned’s substantive relationship with Maxim Group LLC or
sub-agents through which the undersigned is subscribing for Securities predates
Maxim Group LLC’s or such sub-agents’ contact with the undersigned regarding an
investment in the Securities.

    

    (r)           (For
ERISA plans only) The fiduciary of the ERISA plan (the “Plan”) represents
that such fiduciary has been informed of and understands the Company’s
investment objectives, policies and strategies, and that the decision to invest
“plan assets” (as such term is defined in ERISA) in the Company is consistent
with the provisions of ERISA that require diversification of plan assets and
impose other fiduciary responsibilities. The subscriber or Plan fiduciary (a) is
responsible for the decision to invest in the Company; (b) is independent of the
Company and any of its affiliates; (c) is qualified to make such investment
decision; and (d) in making such decision, the subscriber or Plan fiduciary has
not relied primarily on any advice or recommendation of the Company or any of
its affiliates or its agents.

     

    4.            
Registration
Rights

    

    The undersigned shall have registration
rights with respect to the Securities issued and held of record by the
undersigned and the shares of common stock underlying such Securities, as set
forth in greater detail in the Registration Rights Agreement  (the
“Registration Rights
Agreement”) attached hereto as Exhibit
B.

    

    5.            
Insider Trading
Prohibition; Indemnity

    

    (a)           Until
the filing by the Company of a current report on Form 8-K with the SEC
describing, among other things, the Offering, the undersigned hereby agrees to
(i) refrain from (A) engaging in any transactions with respect to the capital
stock of the Company or securities exercisable or convertible into or
exchangeable for any shares of capital stock of the Company, and (B) entering
into any transaction which would have the same effect, or entering into any
swap, hedge or other arrangement that transfers, in whole or in part, any of the
economic consequences of ownership of the capital stock of the Company and (ii)
indemnify and hold harmless the Company, and its respective officers and
directors, employees, counsel, agents, sub-agents and affiliates and each other
person, if any, who controls any of the foregoing, against any loss, liability,
claim, damage and expense whatsoever (including, but not limited to, any and all
expenses whatsoever reasonably incurred in investigating, preparing or defending
against any litigation commenced or threatened or any claim whatsoever) arising
out of or based upon any violation of this Section 5 by the
undersigned.

    

    (b)           The
undersigned agrees to indemnify and hold harmless the Company and its respective
officers and directors, employees, agents, counsel, sub-agents and affiliates
and each other person, if any, who controls any of the foregoing, against any
loss, liability, claim, damage and expense whatsoever (including, but not
limited to, any and all expenses whatsoever reasonably incurred in
investigating, preparing or defending against any litigation commenced or
threatened or any claim whatsoever) arising out of or based upon any false
representation or warranty by the undersigned, or the undersigned’s breach of,
or failure to comply with, any covenant or agreement made by the undersigned
herein or in any other document furnished by the undersigned to the Company and
its respective officers and directors, employees, agents, counsel, sub-agents
and affiliates and each other person, if any, who controls any of the foregoing
in connection with the Offering.

     

    6.            
Conditions to Acceptance
of Subscription

    

    The
Company’s right to accept the subscription of the undersigned is conditioned
upon satisfaction of the following conditions precedent on or before the date
the Company accepts such subscription (any or all of which may be waived by the
undersigned in his, her or its sole discretion) - on the date of the Closing, no
legal action, suit or proceeding shall be pending which seeks to restrain or
prohibit the transactions contemplated by this Agreement.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    

    7.            
Notices to
Subscribers

    

    (a)           THE
UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE
SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE ON
EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH
LAWS. THE SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE
SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE
FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE
ACCURACY OR ADEQUACY OF THE MEMORANDUM. ANY REPRESENTATION TO THE CONTRARY IS
UNLAWFUL.

    

    (b)           IN
MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF
THE PERSON OR ENTITY CREATING THE SECURITIES AND THE TERMS OF THE OFFERING,
INCLUDING THE MERITS AND RISKS INVOLVED.  THE SECURITIES HAVE NOT BEEN
RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY
AUTHORITY.  FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED
THE ACCURACY OR DETERMINED THE ADEQUACY OF THE OFFERING
DOCUMENTS.  ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.  THE UNITS ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE
SECURITIES ACT, AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO
REGISTRATION OR EXEMPTION THEREFROM.  INVESTORS SHOULD BE MADE AWARE
THAT THEY ARE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN
INDEFINITE PERIOD OF TIME.

    

    (c)           THE
PRESENCE OF A LEGEND FOR ANY GIVEN STATE REFLECTS ONLY THAT A LEGEND MAY BE
REQUIRED BY THAT STATE AND SHOULD NOT BE CONSTRUED TO MEAN AN OFFER OR SALE MAY
BE MADE IN ANY PARTICULAR STATE.  THE OFFERING DOCUMENTS MAY BE
SUPPLEMENTED BY ADDITIONAL STATE LEGENDS.  IF YOU ARE UNCERTAIN AS TO
WHETHER OR NOT OFFERS OR SALES MAY BE LAWFULLY MADE IN ANY GIVEN STATE, YOU ARE
ADVISED TO CONTACT THE COMPANY FOR A CURRENT LIST OF STATES IN WHICH OFFERS OR
SALES MAY BE LAWFULLY MADE.  AN INVESTMENT IN THIS OFFERING IS
SPECULATIVE AND INVOLVES A HIGH DEGREE OF FINANCIAL
RISK.  ACCORDINGLY, PROSPECTIVE INVESTORS SHOULD CONSIDER ALL OF THE
RISK FACTORS DESCRIBED HEREIN.

    

    (d)           THE
SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS OFFERING HAS NOT BEEN
QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND
THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE
CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL,
UNLESS THE SALE OF THE SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25000,
25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES
ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE
SALE IS SO EXEMPT.

    

    (e)           FOR
FLORIDA RESIDENTS ONLY.  EACH INVESTOR HAS THE RIGHT TO CANCEL AND
WITHDRAW HIS SUBSCRIPTION AGREEMENT AND HIS PURCHASE OF INTERESTS UPON WRITTEN
NOTICE TO THE COMPANY GIVEN WITHIN THREE BUSINESS DAYS FOLLOWING THE LATER OF
THE MAKING OF THE FIRST PAYMENT BY THE INVESTOR FOR THE SECURITIES PURCHASED OR
THE COMMUNICATION OF THE AVAILABILITY OF SUCH PRIVILEGE TO THE
INVESTOR.  UPON SUCH CANCELLATION OR WITHDRAWAL, THE INVESTOR WILL
HAVE NO OBLIGATION OR DUTY TO THE COMPANY OR TO ANY OTHER PERSON, AND WILL BE
ENTITLED TO THE FULL RETURN OF ANY AMOUNTS PAID BY HIM OR HER PURSUANT TO HIS OR
HER SUBSCRIPTION AGREEMENT.  ANY NOTICE OF CANCELLATION OR WITHDRAWAL
SHOULD BE MADE BY CERTIFIED OR REGISTERED MAIL, AND WILL BE EFFECTIVE UPON
DEPOSIT IN THE UNITED STATES MAIL, POSTAGE OR OTHER TRANSMITTAL FEES
PAID.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    

    8.            
Miscellaneous
Provisions

    

    (a)           Confidential
Information. The subscriber agrees that no portion of the Confidential
Information (as defined below) shall be disclosed to third parties, except as
may be required by law, without the prior express written consent of the
Company; provided,
however, that the
subscriber may share such information with such of its officers and professional
advisors as may need to know such information to assist the subscriber in its
evaluation thereof on the condition that such parties agree to be bound by the
terms hereof. “Confidential
Information” means the existence and terms of this Agreement, the
transactions contemplated hereby, and the disclosures and other information
contained herein or in the agreements in connection with the Offering, excluding
any disclosures or other information that are publicly available.

    

    (b)           Modification. Neither
this Agreement, nor any provisions hereof, shall be waived, modified, discharged
or terminated except by an instrument in writing signed by the party against
whom any waiver, modification, discharge or termination is sought.

    

    (b)           Survival. The
undersigned’s representations and warranties made in this Agreement shall
survive the execution and delivery of this Agreement and the delivery of the
Securities.

    

    (c)           Notices. Any party
may send any notice, request, demand, claim or other communication hereunder to
the undersigned at the address set forth on the signature page of this Agreement
or to the Company at the address set forth above using any means (including
personal delivery, expedited courier, messenger service, fax, ordinary mail or
electronic mail), but no such notice, request, demand, claim or other
communication will be deemed to have been duly given unless and until it
actually is received by the intended recipient. Any party may change the address
to which notices, requests, demands, claims and other communications hereunder
are to be delivered by giving the other parties written notice in the manner
herein set forth.

     

    (d)           Binding Effect.
Except as otherwise provided herein, this Agreement shall be binding upon, and
inure to the benefit of, the parties to this Agreement and their heirs,
executors, administrators, successors, legal representatives and permitted
assigns. If the undersigned is more than one person or entity, the obligation of
the undersigned shall be joint and several and the agreements, representations,
warranties and acknowledgments contained herein shall be deemed to be made by,
and be binding upon, each such person or entity and his or its heirs, executors,
administrators, successors, legal representatives and permitted assigns. This
Agreement sets forth the entire agreement and understanding between the parties
as to the subject matter thereof and merges and supersedes all prior
discussions, agreements and understandings of any and every nature among them,
as to the subject matter hereof.

    

    (e)           Assignability. This
Agreement is not transferable or assignable by the undersigned.

    

    (f)           Governing Law. This
Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware, without giving effect to conflicts of law
principles.

    

    (g)          Counterparts. This
Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same
instrument.

    

    (h)          Further Assurances.
Each of the parties shall execute such documents and perform such further acts
(including, without limitation, obtaining any consents, exemptions,
authorizations, or other actions by, or giving any notices to, or making any
filings with, any governmental authority or any other person) as may be
reasonably required or desirable to carry out or to perform the provisions of
this Agreement.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    

     (i)           Severability. If any
one or more of the provisions contained herein, or the application thereof in
any circumstance, is held invalid, illegal or unenforceable in any respect for
any reason, the validity, legality and enforceability of any such provision in
every other respect and of the remaining provisions hereof shall not be in any
way impaired, unless the provisions held invalid, illegal or unenforceable shall
substantially impair the benefits of the remaining provisions
hereof.

    

    [Remainder of page left intentionally
blank - signature pages follow]

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    ALL SUBSCRIBERS MUST
COMPLETE THIS PAGE

     

    IN WITNESS WHEREOF, the undersigned has
executed this Agreement on the ___ day of April 2010.

     

    
      	
              ________________________

            	
              =

            	
              $_____________________

            
	
              Number
      of shares of the 10% Series

              D
      Convertible Preferred Stock

              subscribed
      hereunder

            	 
      	
                   Aggregate
      Purchase Price

            

    

    

    Manner in
which title is to be held (please check one):

    

    
      
        
          
            	
                    1.

                  	
                    ___

                  	
                    Individual

                  	
                    7.

                  	
                    ___

                  	
                    Trust/Estate/Pension
      or Profit sharing Plan

                    Date
      Opened:______________

                  
	
                    2.

                  	
                    ___

                  	
                    Joint
      Tenants with Right of Survivorship

                  	
                    8.

                  	
                    ___

                  	
                    As
      a Custodian for

                    ________________________________

                    Under
      the Uniform Gift to Minors Act of the State of

                    ________________________________

                  
	
                    3.

                  	
                    ___

                  	
                    Community
      Property

                  	
                    9.

                  	
                    ___

                  	
                    Married
      with Separate Property

                  
	
                    4.

                  	
                    ___

                  	
                    Tenants
      in Common

                  	
                    10.

                  	
                    ___

                  	
                    Keogh

                  
	
                    5.

                  	
                    ___

                  	
                    Corporation/Partnership/
      Limited Liability Company

                  	
                    11.

                  	
                    ___

                  	
                    Tenants
      by the Entirety

                  
	
                    6.

                  	
                    ___

                  	
                    IRA

                  	 
      	 
      	 
      

          

        

      

    

    

    IF MORE
THAN ONE SUBSCRIBER, EACH SUBSCRIBER MUST SIGN.

    INDIVIDUAL
SUBSCRIBERS MUST COMPLETE PAGE 10.

    SUBSCRIBERS
WHICH ARE ENTITIES MUST COMPLETE PAGE 11.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    EXECUTION BY NATURAL
PERSONS

    

    
      
        
          	
                  _____________________________________________________________________________

                  Exact
      Name in Which Title is to be Held

                
	 
      	 
      	 
      
	
                  _________________________________

                   Name
      (Please Print)

                	 
      	
                  _________________________________

                   Name
      of Additional Purchaser

                
	 
      	 
      	 
      
	
                  _________________________________

                   Residence:
      Number and Street

                	 
      	
                  _________________________________

                   Address
      of Additional Purchaser

                
	 
      	 
      	 
      
	
                  _________________________________

                   City,
      State and Zip Code

                	 
      	
                  _________________________________

                   City,
      State and Zip Code

                
	 
      	 
      	 
      
	
                  _________________________________

                   Social
      Security Number

                	 
      	
                  _________________________________

                   
      Social Security Number

                
	 
      	 
      	 
      
	
                  _________________________________

                  Telephone
      Number

                	 
      	
                  _________________________________

                  Telephone
      Number

                
	 
      	 
      	 
      
	
                  _________________________________

                  Fax
      Number (if available)

                	 
      	
                  ________________________________

                  Fax
      Number (if available)

                
	 
      	 
      	 
      
	
                  _________________________________

                  E-Mail
      (if available)

                	 
      	
                  ________________________________

                  E-Mail
      (if available)

                
	 
      	 
      	 
      
	
                  __________________________________

                   (Signature)

                	 
      	
                  ________________________________

                   (Signature
      of Additional Purchaser)

                
	 
      	 
      	 
      
	
                  ACCEPTED
      this __ day of April 2010, on behalf of the Company.

                
	 
      	
                   

                  By:  ______________________________

                          Name:

                          Title:

                

        

      

    

     

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    EXECUTION BY SUBSCRIBER
WHICH IS AN ENTITY

    (Corporation,
Partnership, LLC, Trust, Etc.)

    
      
        
          	
                  _____________________________________________________________________________

                  Name
      of Entity (Please Print)

                
	 
      
	
                  Date
      of Incorporation or Organization:
      ____________________________________________

                
	 
      
	
                  State
      of Principal Office:
      _______________________________________________________

                
	 
      
	
                  Federal
      Taxpayer Identification Number: 
      ___________________________________________

                   

                  ____________________________________________

                  Office
      Address

                   

                  ____________________________________________

                  City,
      State and Zip Code

                   

                  ____________________________________________

                  Telephone
      Number

                   

                  ____________________________________________

                  Fax
      Number (if available)

                   

                  ____________________________________________

                  E-Mail
      (if available)

                
	 
      	 
      
	
                   By:
      _________________________

                          Name:

                          Title:

                	 
      
	 
      	 
      
	
                  ACCEPTED
      this ___ day of _________ 2010, on behalf of the
    Company.

                	 
      
	 
      	
                   

                  By:
      ____________________________

                         Name:

                         Title:

                

        

      

    

     

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    Exhibit
A

    

    CONFIDENTIAL INVESTOR
QUESTIONNAIRE

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

     

    Addendum
A

    

    Cytomedix,
Inc.

    (the
“Company”)

    

    Representations
and warranties of the Company

    in
connection with

    the
Subscription Agreement dated as of April _, 2010

    

    The
Company hereby makes the following representations and warranties:

     

    (a)           Organization and
Qualification. The Company is an entity duly organized, validly existing
and in good standing under the laws of the State of Delaware, with the requisite
power and authority to own and use its properties and assets and to carry on its
business as currently conducted. The Company is duly qualified to conduct
business and is in good standing as a foreign corporation or other entity in
each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be
so qualified or in good standing, as the case may be, could not have or
reasonably be expected to result in (i) an adverse effect on the legality,
validity or enforceability of any Transaction Documents (as defined below), (ii)
a material and adverse effect on the results of operations, assets, prospects,
business or financial condition of the Company, or (iii) an adverse impairment
to the Company’s ability to perform on a timely basis its obligations under any
Offering Documents (any of (i), (ii) or (iii), a “Material Adverse
Effect”).

     

    (b)           Authorization;
Enforcement. The Company has the requisite corporate power and authority
to enter into and to consummate the transactions contemplated by each of this
Agreement and any other documents or agreements executed in connection with the
transactions contemplated hereunder (collectively, the “Transaction Documents”) and otherwise to
carry out its obligations hereunder and thereunder and to issue the Securities
in accordance with the terms hereof and thereof. The execution and delivery of
each of the Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby, including, without limitation,
the issuance of the Securities (as the term is defined in the Subscription
Agreement), have been duly authorized by all necessary action on the part of the
Company and no further action is required by the Company, its Board of Directors
in connection herewith and therewith. Each Transaction Document has been (or
upon delivery will have been) duly executed by the Company and, when delivered
in accordance with the terms hereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in accordance with its
terms, except (a) as such enforceability may be limited by bankruptcy,
insolvency, reorganization or similar laws affecting creditors’ rights
generally, (b) as enforceability of any indemnification and contribution
provisions may be limited under the federal and state securities laws and public
policy, and (c) that the remedy of specific performance and injunctive and other
forms of equitable relief may be subject to equitable defenses and to the
discretion of the court before which any proceeding therefor may be
brought.

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

     

    (c)           No Conflicts. The
execution, delivery and performance of the Transaction Documents by the Company
and the consummation by the Company of the transactions contemplated hereby and
thereby (including, without limitation, the issuance of the Securities) do not
and will not (i) conflict with or violate any provision of the Certificate of
Incorporation, as amended to date, any certificate of designations, preferences
and rights of any outstanding series of preferred stock, or (ii) conflict with,
or constitute a default (or an event that with notice or lapse of time or both
would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time
or both) of, any material agreement, credit facility, debt or other instrument
(evidencing a Company debt or otherwise) or other material understanding to
which the Company is a party or by which any property or asset of the Company is
bound or affected except in the case of each of clauses (i) and (ii), such as
could not, individually or in the aggregate, have or reasonably be expected to
result in a Material Adverse Effect.

     

    (d)          Capitalization. The
Company has an authorized and outstanding capitalization as set forth in the the
SEC Reports (as the term is defined below) as of the dates specified
therein.

    

    (e)           Litigation. There is
no action, suit, proceeding or investigation pending or, to the Company’s
knowledge, threatened against or affecting the Company that questions the
validity of the Transaction Documents or the right of the Company to enter into
such agreements and instruments, or to consummate the transactions contemplated
hereby or thereby, or that would result, either individually or in the
aggregate, in any Material Adverse Effect. The Company is not a party to or, to
the Company’s knowledge, named in or subject to any order, writ, injunction,
judgment or decree of any court, government agency or
instrumentality.

    

    (f)           Offering. Subject to
the truth and accuracy of each investor’s representations set forth in the
Transaction Documents, the offer, sale and issuance of the Securities as
contemplated by the Transaction Documents, are exempt from the registration
requirements of the Securities Act, and neither the Company nor any agent acting
on its behalf will take any action hereafter that would cause the loss of such
exemption.

    

    (g)          Tax Returns. The
Company has filed all tax returns which are required to be filed by it. To the
Company's knowledge, such tax returns are true, correct and complete in all
material respects. All taxes owed by the Company, whether or not shown on any
tax return, have been timely paid.

    

    (h)          Insurance. The
Company is not in default with respect to any insurance policy maintained by
it.

    

    (i)           Finders.  Except
for Maxim Group LLC, there is no investment banker, broker, finder or other
intermediary that has been retained by or is authorized to act on behalf of the
Company who might be entitled to any fee or commission from the Company or any
of its affiliates in connection with the transactions contemplated in the
Offering Documents.

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

     

    (j)           SEC Reports. The
Company has filed all reports required to be filed by it under the 1934 Act,
including pursuant to Section 13(a) or 15(d) thereof, for the twelve months
preceding the date hereof (or such shorter period as the Company was required by
law to file such reports) (the foregoing materials being collectively referred
to herein as the “SEC
Reports”) on a timely basis or has received a valid extension of such
time of filing and has filed any such SEC Reports prior to the expiration of any
such extension. As of their respective dates, the SEC Reports complied in all
material respects with the requirements of the 1934 Act and the rules and
regulations of the SEC promulgated thereunder, and none of the SEC Reports, when
filed and/or subsequently amended or restated, contained any untrue statement of
a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. The financial
statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations
of the SEC with respect thereto as in effect at the time of filing or as
subsequently amended or restated. Such financial statements have been prepared
in accordance with generally accepted accounting principles in the United States
applied on a consistent basis during the periods involved, except as may be
otherwise specified in such financial statements or the notes thereto, and
fairly present in all material respects the financial position of the Company as
of and for the dates thereof and the results of operations and cash flows for
the periods then ended, subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments.

     

      (k)           Disclosure. Neither
the Transaction Documents nor any written statement or certificate made or
delivered by or on behalf of the Company in connection with the Offering (as the
term is defined under the Subscription Agreement) contains any untrue statement
of a material fact or omits to state a material fact necessary to make the
statements herein or therein not misleading.

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

    Exhibit
B

    

    REGISTRATION RIGHTS
AGREEMENT

    
      
         

      

      
        17REGISTRATION RIGHTS
AGREEMENT

     

    This Registration Rights Agreement (the
“Agreement”) is
made and entered into as of this __ day of April _, 2010 by and between
Cytomedix, Inc., a Delaware corporation (the “Company”), and the
parties set forth on the signature pages and Exhibit A hereto
(each, a “Purchaser” and
collectively, the “Purchasers”).

     

    RECITALS

     

    WHEREAS, the Company is
offering to accredited investors in a private placement transaction (the “Offering”) in
compliance with Rule 506 of Regulation D of the Securities Act of 1933, as
amended (the “Securities Act”), up
consisting of: (i) the shares of the 10% Series D Convertible Preferred
Stock (the ”Preferred Stock”) and
(ii) a warrant to purchase shares of Common Stock (a “Warrant”). Each Warrant
shall be exercisable for the number of shares of Common Stock set forth in the
Warrant at the Exercise Price specified in the Warrant for 5 years after the
Closing (the “Warrant
Shares”, and together with the shares underlying the Preferred Stock, the
“Underlying
Securities”) upon the terms and conditions and subject to the provisions
hereinafter set forth; and

    

    WHEREAS, each Purchaser, in
connection with its intent to purchase Securities in the Offering, has executed
and delivered a Subscription Agreement (as hereinafter defined) and a
Confidential Investor Questionnaire (the “Investor
Questionnaire”) memorializing such Purchaser’s agreement to purchase and
the Company’s agreement to sell the number of Securities set forth therein at
the Purchase Price, and this Agreement, pursuant to which the Company will
provide certain registration rights related to the Underlying Securities on the
terms set forth herein (the Subscription Agreement, Investor Questionnaire and
this Agreement are collectively referred to as the “Transaction
Documents”).

    

    NOW, THEREFORE, in
consideration of the mutual promises, representations, warranties, covenants,
and conditions set forth herein, the parties mutually agree as
follows:

    

    1.    Certain
Definitions.  As used in this
Agreement, the following terms shall have the following respective
meanings:

    

    “Approved Market”
means the NASD Over-The-Counter Bulletin Board, the Nasdaq Global Market, the
Nasdaq Capital Market, the New York Stock Exchange, Inc. or the NYSE Amex
LLC.

    

    “Blackout Period”
means, with respect to a registration, a period, in each case commencing on the
day immediately after the Company notifies the Purchasers that they are
required, because of the occurrence of an event of the kind described in Section 4(f) hereof,
to suspend offers and sales of Registrable Securities during which the Company,
in the good faith judgment of its board of directors, determines (because of the
existence of, or in anticipation of, any acquisition, financing activity, or
other transaction involving the Company, or the unavailability for reasons
beyond the Company's control of any required financial statements, disclosure of
information which is in its best interest not to publicly disclose, or any other
event or condition of similar significance to the Company) that the registration
and distribution of the Registrable Securities to be covered by such
registration statement, if any, would be seriously detrimental to the Company
and its stockholders and ending on the earlier of (1) the date upon which the
material non-public information commencing the Blackout Period is disclosed to
the public or ceases to be material and (2) such time as the Company notifies
the selling Holders that the Company will no longer delay such filing of the
Registration Statement, recommence taking steps to make such Registration
Statement effective, or allow sales pursuant to such Registration Statement to
resume; provided, however, that (a) the Company
shall limit its use of Blackout Periods, in the aggregate, to 30 Trading Days in
any 12-month period and (b) no Blackout Period may commence sooner than 60 days
after the end of a prior Blackout Period.

    

    “Business Day” means
any day of the year, other than a Saturday, Sunday, or other day on which the
Commission is required or authorized to close.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    “Closing Date” means
the date of the Closing of the Offering, as determined by the Company and the
Purchasers.

    

    “Commission” means the
Securities and Exchange Commission or any other federal agency at the time
administering the Securities Act.

    

    “Common Stock” means
the common stock of the Company and any and all shares of capital stock or other
equity securities of: (i) the Company which are added to or exchanged or
substituted for the Common Stock by reason of the declaration of any stock
dividend or stock split, the issuance of any distribution or the
reclassification, readjustment, recapitalization or other such modification of
the capital structure of the Company; and (ii) any other corporation, now or
hereafter organized under the laws of any state or other governmental authority,
with which the Company is merged, which results from any consolidation or
reorganization to which the Company is a party, or to which is sold all or
substantially all of the shares or assets of the Company, if immediately after
such merger, consolidation, reorganization or sale, the Company or the
stockholders of the Company own equity securities having in the aggregate more
than 50% of the total voting power of such other corporation.

    

    “Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations
of the Commission promulgated thereunder.

    

    “Family Member” means
(a) with respect to any individual, such individual's spouse, any descendants
(whether natural or adopted), any trust all of the beneficial interests of which
are owned by any of such individuals or by any of such individuals together with
any organization described in Section 501(c)(3) of the Internal Revenue Code of
1986, as amended, the estate of any such individual, and any corporation,
association, partnership or limited liability company all of the equity
interests of which are owned by those above described individuals, trusts or
organizations and (b) with respect to any trust, the owners of the beneficial
interests of such trust.

    

    “Holder” means each
Purchaser or any of such Purchaser's respective successors and Permitted
Assignees who acquire rights in accordance with this Agreement with respect to
the Registrable Securities directly or indirectly from a Purchaser or from any
Permitted Assignee.

    

    “Investor
Questionnaire” has the meaning set forth in the Recitals of this
Agreement.

    

    “Majority Holders”
means at any time Holders representing a majority of the Registrable
Securities.

    

    “Offering” has the
meaning set forth in the Recitals of this Agreement.

    

    “Permitted Assignee”
means (a) with respect to a partnership, its partners or former partners in
accordance with their partnership interests, (b) with respect to a corporation,
its stockholders in accordance with their interest in the corporation, (c) with
respect to a limited liability company, its members or former members in
accordance with their interest in the limited liability company, (d) with
respect to an individual party, any Family Member of such party, (e) an entity
that is controlled by, controls, or is under common control with a transferor or
(f) a party to this Agreement.

    

    “Purchase Price” means
the Purchase Price per Share set forth in the Subscription
Agreement.

    

    “Purchased Securities”
has the meaning set forth in the Recitals of this Agreement.

    

    The terms
“register,” “registered,” and “registration” refer to a registration effected by
preparing and filing a registration statement in compliance with the Securities
Act, and the declaration or ordering of the effectiveness of such registration
statement.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    “Registrable
Securities” means the Underlying Securities, but excluding (i) any
Registrable Securities that have been publicly sold or may be sold immediately
without registration under the Securities Act either pursuant to Rule 144 of the
Securities Act or otherwise; (ii) any Registrable Securities sold by a person in
a transaction pursuant to a registration statement filed under the Securities
Act or (iii) any Registrable Securities that are at the time subject to an
effective registration statement under the Securities Act.

    

    “Registration Default
Date” means the date that is 90 days following the Registration Filing
Date or 120 days following the Registration Filing Date in the event that the
Registration Statement is reviewed by the Commission.

    

    “Registration Default
Period” means the period following the Registration Default Date during
which any Registration Event occurs and is continuing.

    

    “Registration Event”
means the occurrence of any of the following events:

    

    (a)           the
Company fails to file with the Commission the Registration Statement on or
before the Registration Filing Date;

    

    (b)           the
Registration Statement is not declared effective by the Commission on or before
the Registration Default Date;

    

    (c)           after
the SEC Effective Date, sales cannot be made pursuant to the Registration
Statement for any reason (including without limitation by reason of a stop
order, or the Company's failure to update the Registration Statement) except as
excused pursuant to Section 3(a) hereof;
or

    

    (d)           the
Common Stock generally or the Registrable Securities specifically are not listed
or included for quotation on an Approved Market, or trading of the Common Stock
is suspended or halted on the Approved Market, which at the time constitutes the
principal market for the Common Stock, for more than two full, consecutive
Trading Days; provided,
however, a Registration
Event shall not be deemed to occur if all or substantially all trading in equity
securities (including the Common Stock) is suspended or halted on the Approved
Market for any length of time.

    

    “Registration Filing
Date” means the date that is 90 days after the Closing.

    

    “Registration
Statement” means the registration statement that the Company is required
to file pursuant to this Agreement to register the Registrable
Securities.

    

    “Rule 144” means Rule
144 promulgated by the Commission under the Securities Act.

    

    “Securities Act” means
the Securities Act of 1933, as amended, or any similar federal statute
promulgated in replacement thereof, and the rules and regulations of the
Commission thereunder, all as the same shall be in effect at the
time.

    

    “SEC Effective Date”
means the date the Registration Statement is declared effective by the
Commission.

    

    “Securities” has the
meaning set forth in the Recitals of this Agreement.

    

    “Subscription
Agreement” means each of the subscription agreements dated as of the date
hereof by and between the Company and each of the Purchasers setting forth the
terms and conditions of the Offering.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    “Trading Day” means
any day on which the national securities exchange, the Nasdaq Stock Market, the
NYSE Amex LLC, the NASD Over the Counter Bulletin Board or such other securities
market or quotation system, which at the time constitutes the principal
securities market for the Common Stock, is open for general trading of
securities.

    

    “Transaction
Documents” has the meaning set forth in the Recitals of this
Agreement.

    

    2.           Term.  This Agreement
shall continue in full force and effect for a period of two (2) years from the
Effective Date, unless terminated sooner hereunder.

    

    3.           Registration.   Not later
than the Registration Filing Date, the Company shall file with the Commission a
registration statement on Form S-3, or other applicable form, relating to the
resale by the Holders of all of the Registrable Securities, and the Company
shall use its commercially reasonable best efforts to cause such registration
statement to be declared effective prior to the Registration Default Date; provided, however, that the Company
shall not be obligated to effect any such registration, qualification, or
compliance pursuant to this Section, or keep such registration effective
pursuant to the terms hereunder: (i) in any particular jurisdiction in which the
Company would be required to qualify to do business as a foreign corporation or
as a dealer in securities under the securities or blue sky laws of such
jurisdiction or to execute a general consent to service of process in effecting
such registration, qualification or compliance, in each case where it has not
already done so or (ii) during any Blackout Period, in which case the
Registration Filing Date shall be extended to the date immediately following the
last day of such Blackout Period.

    

    Prior to
the SEC Effective Date, the Company will not, without the prior written consent
of the Majority Holders, file or request the acceleration of any other
registration statement filed with the Commission, and during any time subsequent
to the SEC Effective Date when the Registration Statement for any reason is not
available for use by any Holder for the resale of any Registrable Securities,
the Company shall not, without the prior written consent of the Majority
Holders, file any other registration statement or any amendment thereto with the
Commission under the Securities Act or request the acceleration of the
effectiveness of any other registration statement previously filed with the
Commission, other than (i) any registration statement on Form S-8 or Form S-4
and (ii) any registration statement or amendment which the Company is required
to file or as to which the Company is required to request acceleration pursuant
to any obligation in effect on the date of execution and delivery of this
Agreement.

    

    If a
Registration Event occurs, then the Company will make payments to each Purchaser
(a “Qualified
Purchaser”), as partial liquidated damages for the minimum amount of
damages to the Qualified Purchaser by reason thereof, and not as a penalty, at a
rate equal to 1% of the Purchase Price per share of Registrable Securities then
held by a Qualified Purchaser monthly, for each calendar month of the
Registration Default Period (pro rated for any period less than 30 days), up to
a maximum, together with all payments made by the Company to such Purchaser
pursuant hereto, of 6% of the total purchase price of the Securities purchased
by such Purchaser; provided, however, if a Registration
Event occurs (or is continuing) on a date more than six months after the
Qualified Purchaser acquired the Registrable Securities (and thus the six
month  holding period under Rule 144(d) has elapsed), liquidated
damages shall be paid only with respect to that portion of the Qualified
Purchaser's Registrable Securities that cannot then be immediately resold in
reliance on Rule 144. Each such payment shall be due and payable within ten days
after the end of each calendar month of the Registration Default Period until
the termination of the Registration Default Period and within ten days after
such termination.  Such payments shall constitute the Qualified
Purchaser's exclusive remedy for such events. The Registration Default Period
shall terminate upon (i) the filing of the Registration Statement in the case of
clause (a) of the definition of Registration Event, (ii) the SEC Effective Date
in the case of clause (b) of the definition of Registration Event, (iii) the
ability of the Qualified Purchaser to effect sales pursuant to the Registration
Statement in the case of clause (c) of the definition of Registration Event,
(iv) the listing or inclusion and/or trading of the Common Stock on an Approved
Market, as the case may be, in the case of clause (d) of the definition of
Registration Event, and (v) in the case of the events described in clauses (b)
and (c) of the definition of Registration Event, the earlier termination of the
Registration Default Period. The amounts payable as partial liquidated damages
pursuant to this paragraph shall be payable (i) in lawful money of the United
States or, (ii) at the Company’s sole election, in shares of Common Stock, which
such shares shall be issued at the then current market price at the time payment
becomes due. Amounts payable as liquidated damages to each Qualified Purchaser
hereunder with respect to each share of Registrable Securities shall cease when
the Qualified Purchaser no longer holds such shares of Registrable Securities or
such shares of Registrable Securities can be immediately sold by the Qualified
Purchaser in reliance on Rule 144.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    4.           Registration
Procedures.  The Company will
keep each Holder reasonably advised as to the filing and effectiveness of the
Registration Statement. At its expense with respect to the Registration
Statement, the Company will:

    

    (a)          prepare
and file with the Commission with respect to the Registrable Securities, a
registration statement on Form S-3, or any other form for which the Company then
qualifies or which counsel for the Company shall deem appropriate and which form
shall be available for the sale of the Registrable Securities in accordance with
the intended methods of distribution thereof, and use its commercially
reasonable efforts to cause such registration statement to become and remain
effective at for a period of two years or for such shorter period ending on the
earlier to occur of (i) the sale of all Registrable Securities and (ii) the
availability under Rule 144 for the Holder to sell the Registrable Securities
(in either case, the “Effectiveness
Period”);

    

    (b)          if
a registration statement is subject to review by the Commission, promptly
respond to all comments and diligently pursue resolution of any comments to the
satisfaction of the Commission;

    

    (c)          prepare
and file with the Commission such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be
necessary to keep such registration statement effective during the Effectiveness
Period;

    

    (d)          furnish,
without charge, to each Holder of Registrable Securities covered by such
registration statement (i) a reasonable number of copies of such registration
statement (including any exhibits thereto other than exhibits incorporated by
reference), each amendment and supplement thereto as such Holder may reasonably
request, (ii) such number of copies of the prospectus included in such
registration statement (including each preliminary prospectus and any other
prospectus filed under Rule 424 under the Securities Act) as such Holders may
reasonably request, in conformity with the requirements of the Securities Act,
and (iii) such other documents as such Holder may require to consummate the
disposition of the Registrable Securities owned by such Holder, but only during
the Effectiveness Period;

    

    (e)          use
its commercially reasonable best efforts to register or qualify such
registration under such other applicable securities or blue sky laws of such
jurisdictions as any Holder of Registrable Securities covered by such
registration statement reasonably requests and as may be necessary for the
marketability of the Registrable Securities (such request to be made by the time
the applicable registration statement is deemed effective by the Commission) and
do any and all other acts and things necessary to enable such Holder to
consummate the disposition in such jurisdictions of the Registrable Securities
owned by such Holder; provided, however, that the Company
shall not be required to (i) qualify generally to do business in any
jurisdiction where it would not otherwise be required to qualify but for this
paragraph, (ii) subject itself to taxation in any such jurisdiction, or (iii)
consent to general service of process in any such jurisdiction;

    

    (f)           as
promptly as practicable after becoming aware of such event, notify each Holder
of Registrable Securities, the disposition of which requires delivery of a
prospectus relating thereto under the Securities Act, of the happening of any
event, which comes to the Company's attention, that will after the occurrence of
such event cause the prospectus included in such registration statement, if not
amended or supplemented, to contain an untrue statement of a material fact or an
omission to state a material fact required to be stated therein or necessary to
make the statements therein not misleading and the Company shall promptly
thereafter prepare and furnish to such Holder a supplement or amendment to such
prospectus (or prepare and file appropriate reports under the Exchange Act) so
that, as thereafter delivered to the purchasers of such Registrable Securities,
such prospectus shall not contain an untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make
the statements therein not misleading, unless suspension of the use of such
prospectus otherwise is authorized herein or in the event of a Blackout Period,
in which case no supplement or amendment need be furnished (or Exchange Act
filing made) until the termination of such suspension or Blackout
Period;

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    (g)          comply,
and continue to comply during the Effectiveness Period, in all material respects
with the Securities Act and the Exchange Act and with all applicable rules and
regulations of the Commission with respect to the disposition of all securities
covered by such registration statement;

    

    (h)          as
promptly as practicable after becoming aware of such event, notify each Holder
of Registrable Securities being offered or sold pursuant to the Registration
Statement of the issuance by the Commission of any stop order or other
suspension of effectiveness of the Registration Statement;

    

    (i)           use
its best efforts to cause all the Registrable Securities covered by the
Registration Statement to be quoted on the Approved Market on which securities
of the same class or series issued by the Company are then listed or
traded;

    

    (j)           provide
a transfer agent and registrar, which may be a single entity, for the shares of
Common Stock at all times;

    

    (k)           cooperate
with the Holders of Registrable Securities being offered pursuant to the
Registration Statement to issue and deliver, or cause its transfer agent to
issue and deliver, certificates representing Registrable Securities to be
offered pursuant to the Registration Statement within a reasonable time after
the delivery of certificates representing the Registrable Securities to the
transfer agent or the Company, as applicable, and enable such certificates to be
in such denominations or amounts as the Holders may reasonably request and
registered in such names as the Holders may request;

    

    (l)           during
the Effectiveness Period, refrain from bidding for or purchasing any Common
Stock or any right to purchase Common Stock or attempting to induce any person
to purchase any such security or right if such bid, purchase or attempt would in
any way limit the right of the Holders to sell Registrable Securities by reason
of the limitations set forth in Regulation M under the Exchange Act;
and

    

    (m)         take
all other reasonable actions necessary to expedite and facilitate the
disposition by the Holders of the Registrable Securities pursuant to the
Registration Statement.

    

    5.           Suspension
of Offers and Sales.  Each Holder
agrees that, upon receipt of any notice from the Company of the happening of any
event of the kind described in Section 4(f) hereof
or of the commencement of an Blackout Period, such Holder shall discontinue the
disposition of Registrable Securities included in the Registration Statement
until such Holder's receipt of the copies of the supplemented or amended
prospectus contemplated by Section 4(f) hereof
or notice of the end of the Blackout Period, and, if so directed by the Company,
such Holder shall deliver to the Company (at the Company's expense) all copies
(including, without limitation, any and all drafts), other than permanent file
copies, then in such Holder's possession, of the prospectus covering such
Registrable Securities current at the time of receipt of such
notice.

    

    6.           Registration
Expenses.  The Company shall
pay all expenses in connection with any registration obligation provided herein,
including, without limitation, all registration, filing, stock exchange fees,
printing expenses, all fees and expenses of complying with securities or blue
sky laws, and the fees and disbursements of counsel for the Company and of its
independent accountants; provided that, in any underwritten registration, each
party shall pay for its own underwriting discounts and commissions and transfer
taxes. Except as provided in this Section and Section 9 hereof, the
Company shall not be responsible for the expenses of any attorney or other
advisor employed by a Holder.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    7.           Assignment
of Rights.  No Holder may
assign its rights under this Agreement to any party without the prior written
consent of the Company; provided, however, that a Holder may
assign its rights under this Agreement without such consent to a Permitted
Assignee as long as (a) such transfer or assignment is effected in accordance
with applicable securities laws; (b) such transferee or assignee agrees in
writing to become subject to the terms of this Agreement; and (c) the Company is
given written notice by such Holder of such transfer or assignment, stating the
name and address of the transferee or assignee and identifying the Registrable
Securities with respect to which such rights are being transferred or
assigned.

    

    8.           Information
by Holder.  Holders included
in any registration shall furnish to the Company such information as the Company
may reasonably request in writing regarding such Holders and the distribution
proposed by such Holders.

    

    9.      
     Indemnification.

    

    (a)          In
the event of the offer and sale of Registrable Securities under the Securities
Act, the Company shall, and hereby does, indemnify and hold harmless, to the
fullest extent permitted by law, each Holder, its directors, officers, partners,
each other person who participates as an underwriter in the offering or sale of
such securities, and each other person, if any, who controls or is under common
control with such Holder or any such underwriter within the meaning of Section
15 of the Securities Act, against any losses, claims, damages or liabilities,
joint or several, and expenses to which the Holder or any such director,
officer, partner or underwriter or controlling person may become subject under
the Securities Act or otherwise, insofar as such losses, claims, damages,
liabilities or expenses (or actions or proceedings, whether commenced or
threatened, in respect thereof) arise out of or are based upon any untrue
statement of any material fact contained in any registration statement prepared
and filed by the Company under which shares of Registrable Securities were
registered under the Securities Act, any preliminary prospectus, final
prospectus or summary prospectus contained therein, or any amendment or
supplement thereto, or any omission to state therein a material fact required to
be stated therein or necessary to make the statements therein in light of the
circumstances in which they were made not misleading, and the Company shall
reimburse the Holder, and each such director, officer, partner, underwriter and
controlling person for any legal or any other expenses reasonably incurred by
them in connection with investigating, defending or settling any such loss,
claim, damage, liability, action or proceeding; provided that the Company shall
not be liable in any such case (i) to the extent that any such loss, claim,
damage, liability (or action or proceeding in respect thereof) or expense arises
out of or is based upon an untrue statement in or omission from such
registration statement, any such preliminary prospectus, final prospectus,
summary prospectus, amendment or supplement in reliance upon and in conformity
with written information furnished to the Company through an instrument duly
executed by or on behalf of such Holder specifically stating that it is for use
in the preparation thereof or (ii) if the person asserting any such loss, claim,
damage, liability (or action or proceeding in respect thereof) who purchased the
Registrable Securities that are the subject thereof did not receive a copy of an
amended preliminary prospectus or the final prospectus (or the final prospectus
as amended or supplemented) at or prior to the written confirmation of the sale
of such Registrable Securities to such person because of the failure of such
Holder or underwriter to so provide such amended preliminary or final prospectus
and the untrue statement or omission of a material fact made in such preliminary
prospectus was corrected in the amended preliminary or final prospectus (or the
final prospectus as amended or supplemented). Such indemnity shall remain in
full force and effect regardless of any investigation made by or on behalf of
the Holders, or any such director, officer, partner, underwriter or controlling
person and shall survive the transfer of such shares by the
Holder.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    (b)          As
a condition to including Registrable Securities in any registration statement
filed pursuant to this Agreement, each Holder agrees to be bound by the terms of
this Section 9
and to indemnify and hold harmless, to the fullest extent permitted by law, the
Company, its directors and officers, and each other person, if any, who controls
the Company within the meaning of Section 15 of the Securities Act, against any
losses, claims, damages or liabilities, joint or several, to which the Company
or any such director or officer or controlling person may become subject under
the Securities Act or otherwise, insofar as such losses, claims, damages or
liabilities (or actions or proceedings, whether commenced or threatened, in
respect thereof) that arises out of or is based upon an untrue statement in or
omission from such registration statement, any such preliminary prospectus,
final prospectus, summary prospectus, amendment or supplement in reliance upon
and in conformity with written information furnished to the Holder through an
instrument duly executed by or on behalf of the Company specifically stating
that it is for use in the preparation thereof, and such Holder shall reimburse
the Company, and each such director, officer, and controlling person for any
legal or other expenses reasonably incurred by them in connection with
investigating, defending, or settling and such loss, claim, damage, liability,
action, or proceeding; provided, however, that such indemnity
agreement found in this Section 9 shall in no
event exceed the gross proceeds from the offering received by such Holder. Such
indemnity shall remain in full force and effect, regardless of any investigation
made by or on behalf of the Company or any such director, officer or controlling
person and shall survive the transfer by any Holder of such shares.

    

    (c)          Promptly
after receipt by an indemnified party of notice of the commencement of any
action or proceeding involving a claim referred to in this Section (including
any governmental action), such indemnified party shall, if a claim in respect
thereof is to be made against an indemnifying party, give written notice to the
indemnifying party of the commencement of such action; provided that the failure
of any indemnified party to give notice as provided herein shall not relieve the
indemnifying party of its obligations under this Section, except to the extent
that the indemnifying party is actually prejudiced by such failure to give
notice. In case any such action is brought against an indemnified party, unless
in the reasonable judgment of counsel to such indemnified party a conflict of
interest between such indemnified and indemnifying parties may exist or the
indemnified party may have defenses not available to the indemnifying party in
respect of such claim, the indemnifying party shall be entitled to participate
in and to assume the defense thereof, with counsel reasonably satisfactory to
such indemnified party and, after notice from the indemnifying party to such
indemnified party of its election so to assume the defense thereof, the
indemnifying party shall not be liable to such indemnified party for any legal
or other expenses subsequently incurred by the latter in connection with the
defense thereof, unless in such indemnified party's reasonable judgment a
conflict of interest between such indemnified and indemnifying parties arises in
respect of such claim after the assumption of the defenses thereof or the
indemnifying party fails to defend such claim in a diligent manner, other than
reasonable costs of investigation. Neither an indemnified nor an indemnifying
party shall be liable for any settlement of any action or proceeding effected
without its consent. No indemnifying party shall, without the consent of the
indemnified party, consent to entry of any judgment or enter into any
settlement, which does not include as an unconditional term thereof the giving
by the claimant or plaintiff to such indemnified party of a release from all
liability in respect of such claim or litigation.  Notwithstanding
anything to the contrary set forth herein, and without limiting any of the
rights set forth above, in any event any party shall have the right to retain,
at its own expense, counsel with respect to the defense of a claim.

    

    (d)          In
the event that an indemnifying party does or is not permitted to assume the
defense of an action pursuant to Section 9(c) hereof
or in the case of the expense reimbursement obligation set forth in Sections 9(a) and
(b) hereof, the
indemnification required by Sections 9(a) and
(b) hereof
shall be made by periodic payments of the amount thereof during the course of
the investigation or defense, as and when bills received or expenses, losses,
damages, or liabilities are incurred.

    

    (e)          If
the indemnification provided for in this Section is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any loss,
liability, claim, damage or expense referred to herein, the indemnifying party,
in lieu of indemnifying such indemnified party hereunder, shall (i) contribute
to the amount paid or payable by such indemnified party as a result of such
loss, liability, claim, damage or expense as is appropriate to reflect the
proportionate relative fault of the indemnifying party on the one hand and the
indemnified party on the other (determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission
relates to information supplied by the indemnifying party or the indemnified
party and the parties' relative intent, knowledge, access to information and
opportunity to correct or prevent such untrue statement or omission), or (ii) if
the allocation provided by clause (i) above is not permitted by applicable law
or provides a lesser sum to the indemnified party than the amount hereinafter
calculated, not only the proportionate relative fault of the indemnifying party
and the indemnified party, but also the relative benefits received by the
indemnifying party on the one hand and the indemnified party on the other, as
well as any other relevant equitable considerations. No indemnified party guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any indemnifying party
who was not guilty of such fraudulent misrepresentation.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    (f)           Other
Indemnification.  Indemnification
similar to that specified in this Section (with appropriate modifications) shall
be given by the Company and each Holder of Registrable Securities with respect
to any required registration or other qualification of securities under any
federal or state law or regulation or governmental authority other than the
Securities Act.

    

    10.    
     Rule
144.  For a period of
at least 24 months following the Closing Date, the Company will use its
commercially reasonable best efforts to timely file all reports required to be
filed by the Company after the date hereof under the Securities Act and the
Exchange Act and the rules and regulations adopted by the Commission thereunder,
and if the Company is not required to file reports pursuant to such sections, it
will prepare and furnish to the Purchasers and make publicly available in
accordance with Rule 144(c) such information as is required for the Purchasers
to sell shares of Common Stock under Rule 144.

    

    11.    
     Independent
Nature of Each Purchaser's Obligations and Rights.  The obligations
of each Purchaser under this Agreement are several and not joint with the
obligations of any other Purchaser, and each Purchaser shall not be responsible
in any way for the performance of the obligations of any other Purchaser under
this Agreement. Nothing contained herein and no action taken by any Purchaser
pursuant hereto, shall be deemed to constitute such Purchasers as a partnership,
an association, a joint venture, or any other kind of entity, or create a
presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by this
Agreement. Each Purchaser shall be entitled to independently protect and enforce
its rights, including without limitation the rights arising out of this
Agreement, and it shall not be necessary for any other Purchaser to be joined as
an additional party in any proceeding for such purpose.

    

    12.     
    Miscellaneous.

    

    (a)        
 Governing
Law. This
Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware, both substantive and remedial, excluding that body of law
relating to conflict of laws.

    

    (b)          Successors
and Assigns.  Except as
otherwise provided herein, the provisions hereof shall inure to the benefit of,
and be binding upon, the successors, Permitted Assignees, executors and
administrators of the parties hereto. In the event the Company merges with, or
is otherwise acquired by, a direct or indirect subsidiary of a publicly traded
company, the Company shall condition the merger or acquisition on the assumption
by such parent company of the Company's obligations under this
Agreement.

    

    (c)      
    Entire
Agreement.  This Agreement
constitutes the full and entire understanding and agreement between the parties
with regard to the subjects hereof.

    

    (d)          Notices,
etc.  All
notices or other communications which are required or permitted under this
Agreement shall be in writing and sufficient if delivered by hand, by facsimile
transmission, by registered or certified mail, postage pre-paid, by electronic
mail, or by courier or overnight carrier, to the persons at the addresses set
forth below (or at such other address as may be provided hereunder), and shall
be deemed to have been delivered as of the date so delivered:

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    if to the
Company to:

    

    Cytomedix,
Inc.

    416
Hungerford Drive, Suite 330

    Rockville,
MD 20850

    Attention:  Martin
Rosendale, CEO

    Telephone
No.: 240-499-2680

    

    With a
copy to:

     

    Cozen
O’Connor

    1627 I
Street NW, Suite 1100

    Washington,
DC 20006

    Attention:
Alec Orudjev, Esq.

    Telephone
No.: 202-912-4842

    if to the
Purchasers:

    

                      To
each Purchaser at the address set forth on Exhibit A
hereto.

    

    or at
such other address as any party shall have furnished to the other parties in
writing.

    

    (e)          Delays or
Omissions.  No delay or
omission to exercise any right, power or remedy accruing to any Holder, upon any
breach or default of the Company under this Agreement, shall impair any such
right, power or remedy of such Holder nor shall it be construed to be a waiver
of any such breach or default, or an acquiescence therein, or of or in any
similar breach or default thereunder occurring; nor shall any waiver of any
single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or approval of
any kind or character on the part of any Holder of any breach or default under
this Agreement, or any waiver on the part of any Holder of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to
the extent specifically set forth in such writing. All remedies, either under
this Agreement, or by law or otherwise afforded to any holder, shall be
cumulative and not alternative.

    

    (f)           Counterparts.  This Agreement
may be executed in any number of counterparts, each of which shall be
enforceable against the parties actually executing such counterparts, and all of
which together shall constitute one instrument. In the event that any signature
is delivered by facsimile transmission, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile signature page
were an original thereof.

    

    (g)          Severability.  In the case any
provision of this Agreement shall be invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.

    

    (h)          Amendments.  The provisions of
this Agreement may be amended at any time and from time to time, and particular
provisions of this Agreement may be waived, with and only with an agreement or
consent in writing signed by the Company and the Majority Holders. The
Purchasers acknowledge that by the operation of this Section, the Majority
Holders may have the right and power to diminish or eliminate all rights of the
Purchasers under this Agreement.

    

    (i)           Limitation
on Subsequent Registration Rights.  After the date of
this Agreement, the Company shall not, without the prior written consent of the
Majority Holders, enter into any agreement with any holder or prospective holder
of any securities of the Company that would grant such holder registration
rights senior to those granted to the Holders hereunder.

    

    [SIGNATURE
PAGES FOLLOW]

    

    This Registration Rights Agreement is
hereby executed as of the date first above written.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    

    
      
        
          	
                  CYTOMEDIX,
      INC.

                
	 
      	 
      
	
                  By:

                	 
      
	
                  Name:  Martin
      Rosendale

                
	
                  Title:
       Chief Executive
Officer

                

        

      

    

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    This Registration Rights Agreement is
hereby executed as of the date first above written.

    

    
      
        
          
            
              	
                      PURCHASER:

                    
	 
      
	 
      
	
                      (PRINT
      NAME)

                    
	 
      	 
      
	
                      By:

                    	 
      
	 
      	
                      Name:

                    
	 
      	
                      Its:

                    

            

          

        

      

    

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    Exhibit
A

    

    Purchasers

    

    
      
        
          
            
              	
                      Purchaser Name

                    	 	
                      Purchaser Address

                    	 	
                      Number of Securities

                    
	 
      	 	 
      	 	 
      
	 
      	 	 
      	 	 
      
	 
      	 	 
      	 	 
      
	 
      	 	 
      	 	 
      
	 
      	 	 
      	 	 
      
	 
      	 	 
      	 	 
      
	 
      	 	 
      	 	 
      

            

          

        

      

    

    
      
         

      

      
        13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]